Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.62 |
| ▸ | MEN1 | O00255 | 5/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.59 |
| ▸ | CES2 | O00748 | 1/20 | 0.58 |
| ▸ | CES1 | P23141 | 1/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | KMO | O15229 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1110091 | 0.87 | KMT2A (0.62) | KMT2AMEN1ALDH1A1CES2CES1 | |
| SCHEMBL18300806 | 0.87 | KMT2A (0.60) | KMT2AMEN1ALDH1A1CES2CES1 | |
| SCHEMBL5869531 | 0.86 | MAPT (0.62) | KMT2AMEN1ALDH1A1CES2CES1 | |
| SCHEMBL27570821 | 0.84 | ALDH1A1 (0.68) | KMT2AMEN1ALDH1A1CES2CES1 | |
| SCHEMBL8921654 | 0.84 | ALDH1A1 (0.68) | KMT2AMEN1ALDH1A1CES2CES1 | |
| SCHEMBL38656427 | 0.84 | ALDH1A1 (0.68) | KMT2AMEN1ALDH1A1CES2CES1 | |
| SCHEMBL1420765 | 0.83 | TP53 (0.67) | KMT2AMEN1ALDH1A1CES2CES1 | |
| SCHEMBL1420764 | 0.83 | TP53 (0.67) | KMT2AMEN1ALDH1A1CES2CES1 | |
| SCHEMBL11673189 | 0.83 | ALDH1A1 (0.54) | KMT2AMEN1ALDH1A1CES2CES1 | |
| SCHEMBL10790549 | 0.81 | TSHR (0.68) | KMT2AMEN1ALDH1A1CES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12227496-B2 | Substituted bicyclic compounds as farnesoid X receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-02-18 | — | — | US | disclosed |
| US-11713312-B2 | Substituted bicyclic compounds as farnesoid X receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-08-01 | — | — | US | disclosed |
| US-11713312-B2 | Substituted bicyclic compounds as farnesoid X receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-08-01 | — | — | US | disclosed |
| US-20230109670-A9 | SUBSTITUTED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2023-04-06 | — | — | US | disclosed |
| US-20220162201-A1 | SUBSTITUTED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2022-05-26 | — | — | US | disclosed |
| US-20220135550-A1 | SUBSTITUTED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2022-05-05 | — | — | US | disclosed |
| US-11254663-B2 | Substituted bicyclic compounds as farnesoid X receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-02-22 | — | — | US | disclosed |
| EP-3924336-A1 | SUBSTITUTED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | Bristol-Myers Squibb Company (US) | 2021-12-22 | — | — | EP | disclosed |
| CN-113710656-A | Substituted bicyclic compounds as farnesoid X receptor modulators | 百时美施贵宝公司 | 2021-11-26 | — | — | CN | disclosed |
| CN-113677666-A | Substituted bicyclic compounds as farnesoid X receptor modulators | 百时美施贵宝公司 | 2021-11-19 | — | — | CN | disclosed |
| WO-2020168143-A1 | SUBSTITUTED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-08-20 | — | — | WO | disclosed |
| US-4829076-A | CARDIOVASCULAR DISORDERS | ALKALOIDA VEGYESZETI GYAR (HU) | 1989-05-09 | — | — | US | disclosed |
| US-4041158-A | INSECTICIDES | BAYER AKTIENGESELLSCHAFT (DT) | 1977-08-09 | — | — | US | disclosed |
| US-4026709-A | Color photographic recording material | CIBA-GEIGY AG (CH) | 1977-05-31 | — | — | US | disclosed |
| US-3984432-A | PHOSPHONIC ACID AND PHOSPHORIC ACID DERIVATIVES | CIBA-GEIGY AG (CH) | 1976-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12227496-B2 | Substituted bicyclic compounds as farnesoid X receptor modulators | FXR1, NR1H4, FXR2 | KMT2A 4180/4885MEN1 2710/4885ALDH1A1 2882/4885 |
| US-20230109670-A9 | SUBSTITUTED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | FXR1, NR1H4, FXR2 | KMT2A 4180/4885MEN1 2710/4885ALDH1A1 2882/4885 |
| US-20220135550-A1 | SUBSTITUTED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | FXR1, NR1H4, FXR2 | KMT2A 4497/4885MEN1 3478/4885ALDH1A1 2862/4885 |
| US-11254663-B2 | Substituted bicyclic compounds as farnesoid X receptor modulators | FXR1, NR1H4, FXR2 | KMT2A 4497/4885MEN1 3478/4885ALDH1A1 2862/4885 |
| US-20220162201-A1 | SUBSTITUTED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | FXR1, NR1H4, FXR2 | KMT2A 4180/4885MEN1 2710/4885ALDH1A1 2882/4885 |
| US-11713312-B2 | Substituted bicyclic compounds as farnesoid X receptor modulators | FXR1, NR1H4, FXR2 | KMT2A 4497/4885MEN1 3478/4885ALDH1A1 2862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.